[Federal Register Volume 75, Number 158 (Tuesday, August 17, 2010)]
[Notices]
[Pages 50768-50769]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-20274]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
A Novel Scaffold for Multivalent Display of Ligands
Description of Invention: Multivalent interactions are important in
cell attachment, wound healing and immune responses. Such interactions
are associated with cancer metastasis, blood clotting and the
generation of antibodies from a vaccination. Mimicking multivalent
interactions on a synthetic scaffold is challenging especially when
large numbers of ligands (such as 5 or more) need to be displayed.
There are numerous synthetic scaffolds that have been developed, but
there are significant limitations that remain.
Scientists at the NIH have designed a novel multivalent scaffold
that can display anywhere from 1 to 200 ligands. This system allows
different types of ligands to be displayed in a controlled, spatially-
addressable manner. This system uses peptide nucleic acids (PNAs)
containing [gamma]-substituted side
[[Page 50769]]
chains. PNAs are synthetic molecules that possess the bases derived
from DNA. This invention could revolutionize the way in which
multivalent display is used in research as well as help make
vaccinations or prevent disease.
Applications:
Controlled interactions ensure only a single stoichiometry
is attained.
Simple access to a wide range of multivalent platforms.
Development Status: Early stage.
Inventors: Daniel Appella et al. (NIDDK).
Patent Status: U.S. Provisional Application No. 61/333,442 filed 11
May 2010 (HHS Reference No. E-129-2010/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Charlene Sydnor, PhD; 301-435-4689;
[email protected].
Collaborative Research Opportunity: The NIDDK Laboratory of
Bioorganic Chemistry is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize this novel scaffold or to collaborate on
related laboratory interests. Please contact Marguerite J. Miller at
301-496-9003 and/or [email protected] for more information.
N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as
A3 Receptor Agonists
Description of Invention: This technology relates to specific (N)-
methanocarba adenine nucleosides that have been developed and
dendrimers that connect these compounds to create molecules with
multiple targets. Dendrimers are essentially repeated molecular
branches presenting the core receptor-binding molecules. The compounds
synthesized function as agonists and antagonists of a receptor of the
G-protein coupled receptor (GPCR) superfamily. In particular, the
receptors of interest for this invention include A3
adenosine receptors and agonists and antagonists of P2Y receptors, such
as P2Y1 and P2Y14.
Dendrimer conjugates may have one or more advantages, such as
increased solubility, reduced toxicity, and improved pharmacokinetic
properties. They can also be used to connect other types of molecules
without affecting the agonist or antagonists properties. For instance,
molecules such as those used for imaging or tracing can be added.
Dendrimers can also be used to link more than one type of agonist or
antagonist to confer multiple functionalities. This technology provides
a novel mechanism to treat a number of disorders related to
dysregulation of A3 adenosine receptors.
Applications:
Cardiac arrhythmias or ischemia
Inflammation
Stroke
Diabetes
Asthma
Cancer
Imaging
Development Status: Research quantities of compounds have been
synthesized and tested for receptor selectivity.
Inventors: Kenneth A Jacobson and Dilip K. Tosh (NIDDK).
Patent Status:
U.S. Provisional Application No. 61/266,084 filed 02 Dec 2009 (HHS
Reference No. E-049-2010/0-US-01).
U.S. Provisional Application No. 61/313,961 filed 15 Mar 2010 (HHS
Reference No. E-049-2010/1-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Steven Standley, PhD; 301-435-4074;
[email protected].
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic
Chemistry, Molecular Recognition Section, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact Dr. Kenneth Jacobson at
[email protected] for more information.
Species-Independent A3 Adenosine Receptor Agonists Which May
Be Useful for Treating Ischemia, Controlling Inflammation, and
Regulating Cell Proliferation
Description of Invention: This invention claims species-independent
agonists of A3AR, specifically (N)-methanocarba adenine
nucleosides and pharmaceutical compositions comprising such
nucleosides. The A3 adenosine receptor (A3AR)
subtype has been linked with helping protect the heart from ischemia,
controlling inflammation, and regulating cell proliferation. Agonists
of the human A3AR subtype have been developed that are also
selective for the mouse A3AR while retaining selectivity for
the human receptor. This solves a problem for clinical development
because animal model testing is important for pre-clinical validation
of drug function. Novel agonists have been made that exhibit as much as
6000x selectivity for A3 versus A1 in humans
while retaining at least 400x selectivity for A3 versus
A1 in mice. In addition, the molecules of the invention
exhibit very low nanomolar affinity. This innovation will not only
facilitate moving A3 agonists into the clinical phase of
drug development by being more amenable to animal studies, but also
provide much greater selectivity in humans, and thereby potentially
fewer side effects than drugs currently undergoing clinical trials.
Applications:
Cardiac arrhythmias or ischemia
Inflammation
Stroke
Diabetes
Asthma
Cancer
Development Status: Research quantities of compounds have been
synthesized and tested for receptor selectivity.
Inventors: Kenneth A. Jacobson and Artem Melman (NIDDK).
Publication: A Melman et al. Design of (N)-methanocarba adenosine
5'-uronamides as species-independent A3 receptor-selective
agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-2819. [PubMed:
18424135].
Patent Status: PCT Application No. PCT/US09/38026 filed 24 Mar
2009, which published as WO 2009/123881 on 08 Oct 2009 (HHS Reference
No. E-140-2008/0-PCT-02).
Licensing Status: Available for licensing.
Licensing Contact: Steven Standley, Ph.D.; 301-435-4074;
[email protected].
Collaborative Research Opportunity: The NIDDK Laboratory of
Bioorganic Chemistry is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize A3 Adenosine Receptor Agonists.
Please contact Marguerite J. Miller at 301-496-9003 or
[email protected] for more information.
Dated: August 11, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-20274 Filed 8-16-10; 8:45 am]
BILLING CODE 4140-01-P